Trial Profile

Clinical study of ileal bile acid transporter inhibitor on changes in bowel movements and various metabolic markers in type 2 diabetic patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elobixibat (Primary)
Indications Constipation
Focus Pharmacodynamics

Most Recent Events

15 Sep 2022 Primary endpoint (The change in hemoglobin (Hb) A(1c) at week 12) has been met, as per results published in the Clinical Therapeutics.
15 Sep 2022 Results assessing the metabolic effects of elobixibat in patients with type 2 diabetes mellitus (T2DM)-related constipation, published in the Clinical Therapeutics.
22 Sep 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com